MDF, 2024. Pepgen Receives u.s. Fda Fast Track Designation for PGN-Edodm1 for the Treatment of Myotonic Dystrophy Type 1, MDF: Myotonic Dystrophy Foundation.
United States of America.
Retrieved from https://coilink.org/20.500.12592/5po0tkm on 15 Nov 2024. COI: 20.500.12592/5po0tkm.